Worth reading
46Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
403
¥ million (year-on-year decrease in operating profit)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationQ3 FY202611 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥10,467 million+4.1%
Operating profit¥509 million-44.2%
Ordinary income¥568 million-34.8%
Net income¥301 million-54.7%
Gross Profit Margin41.0%
Operating profit margin4.9%
Selling, general and administrative expenses¥3,785 million
Full-year earnings forecast
Net Sales
¥13,960 million
Costs of sales
¥8,065 million
Gross profit
¥5,895 million
Selling, general and administrative expenses
¥5,135 million
Operating profit
¥760 million
Ordinary income
¥800 million
Net income for the current fiscal year
¥560 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue growth factors: new urological products in direct sales, urological products in export sales, and increased orders for OEM sales. Factors behind the decline in profit: the impact of the weaker yen on products purchased overseas, deterioration in the cost ratio caused by China's centralized purchasing, and costs related to strengthening overseas operations and M&A. No amounts are disclosed by factor.
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
2 new products launched in the first half, the transition to the European MDR, expansion of China's centralized purchasing system, commencement of operations by the Indian sales company, and continued strong performance by new products launched in 2024New initiatives
- Making 4 companies in the Globits Group subsidiaries
- Establishment of CREATE MEDIC INDIA PVT. LTD., a sales company in India
- Entry into the US market and introduction of cutting-edge products
- Global expansion of the FDA consulting business
Key KPIsA metric the company considers important as a management benchmark.
- Overseas revenue ratio33.8 %
- Number of employees (consolidated)1,010 people
- Product lineupMore than 100 types
Medium-term management plan targets
2027
Operating profit¥13 hundred million
Operating profit margin¥8 hundred million
Operating profit margin unit%
Overseas revenue¥57 hundred million
Overseas sales unit¥ hundred million
2034
Operating profit¥30 hundred million
Operating profit margin¥15 hundred million
Operating profit margin unit%
Overseas revenue¥100 hundred million
Overseas sales unit¥ hundred million
Overseas revenue ratio¥50 hundred million
Overseas sales ratio unit%
Financial targets
ROE
2025 actual4.4 %
2027 target7 %
Operating profit margin
2025 actual7.4 %
2027 target8 %
PBR
2025 actual0.53 times
2027 target0.7 times
Number of stores and locations
References are made to locations including 2 sites in the United States, but the number of sites at period-end and the number of openings and closures during the period are not disclosed.Number of employees
Number of Employees1,010 people
As ofEnd of December 2025
Annual Dividend
Dividend forecast for fiscal 2026¥47
Interim¥20
End of period¥27
Payout ratio
50Acquisition of treasury shares
¥200 million was implemented in fiscal 2025. Share buybacks totaled ¥493 million as of the end of September 2026. The company plans to continue implementing buybacks flexibly. The acquisition period and number of shares are not disclosed.| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Q3 FY2026 |
| Net Sales | ¥10,467 million (YoY +4.1%) |
| Operating profit | ¥509 million (YoY -44.2%) |
| Ordinary income | ¥568 million (YoY -34.8%) |
| Net income | ¥301 million (YoY -54.7%) |
| Gross Profit Margin | 41.0% |
| Operating profit margin | 4.9% |
| Selling, general and administrative expenses | ¥3,785 million |
| Full-year earnings forecast | Net Sales ¥13,960 million / Costs of sales ¥8,065 million / Gross profit ¥5,895 million / Selling, general and administrative expenses ¥5,135 million / Operating profit ¥760 million / Ordinary income ¥800 million / Net income for the current fiscal year ¥560 million |
| Breakdown of Factors Affecting the Change | Revenue growth factors: new urological products in direct sales, urological products in export sales, and increased orders for OEM sales. Factors behind the decline in profit: the impact of the weaker yen on products purchased overseas, deterioration in the cost ratio caused by China's centralized purchasing, and costs related to strengthening overseas operations and M&A. No amounts are disclosed by factor. |
| Key KPIs | Indicator name Overseas revenue ratio / Value 33.8 % / Year on year against the same period last year Not disclosed, Indicator name Number of employees (consolidated) / Value 1,010 people / Year on year against the same period last year Not disclosed, Indicator name Product lineup / Value More than 100 types / Year on year against the same period last year Not disclosed |
| Number of stores and locations | References are made to locations including 2 sites in the United States, but the number of sites at period-end and the number of openings and closures during the period are not disclosed. |
| Number of employees | Number of Employees 1,010 people / As of End of December 2025 / Changes during the period and hiring plan Not disclosed |
| Assumptions Underlying the Business Outlook | 2 new products launched in the first half, the transition to the European MDR, expansion of China's centralized purchasing system, commencement of operations by the Indian sales company, and continued strong performance by new products launched in 2024 |
| Medium-term management plan targets | 2027 Operating profit ¥13 hundred million / Operating profit margin ¥8 hundred million / Operating profit margin unit % / Overseas revenue ¥57 hundred million / Overseas sales unit ¥ hundred million / 2034 Operating profit ¥30 hundred million / Operating profit margin ¥15 hundred million / Operating profit margin unit % / Overseas revenue ¥100 hundred million / Overseas sales unit ¥ hundred million / Overseas revenue ratio ¥50 hundred million / Overseas sales ratio unit % |
| Financial targets | ROE 2025 actual 4.4 % / 2027 target 7 % / Operating profit margin 2025 actual 7.4 % / 2027 target 8 % / PBR 2025 actual 0.53 times / 2027 target 0.7 times |
| Annual Dividend | Dividend forecast for fiscal 2026 ¥47 / Interim ¥20 / End of period ¥27 |
| Payout ratio | 50 |
| Acquisition of treasury shares | ¥200 million was implemented in fiscal 2025. Share buybacks totaled ¥493 million as of the end of September 2026. The company plans to continue implementing buybacks flexibly. The acquisition period and number of shares are not disclosed. |
| New initiatives | Making 4 companies in the Globits Group subsidiaries, Establishment of CREATE MEDIC INDIA PVT. LTD., a sales company in India, Entry into the US market and introduction of cutting-edge products, Global expansion of the FDA consulting business |
Items this document does not state (10)
Results for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsRisk amount incorporated into the outlookCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.New urological products performed well in direct sales, but operating income declined due to the impact of the weaker yen on products purchased overseas, deterioration in the cost ratio caused by China's centralized purchasing, and costs related to strengthening overseas operations and M&A.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.